ERBB2 and gastroesophageal junction adenocarcinoma: Trastuzumab, a monoclonal antibody targeting HER-2 inducing an immune-mediated response that causes internalization and downregulation of HER-2, is an approved first-line treatment for patients with aGC/GEJ adenocarcinoma with HER-2 overexpression.